| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) | Phase 2 Clinical | Genenta Science Srl | Carcinoma, Renal Cell; Glioblastoma; Multiple Myeloma | Details | |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | Details |
| recombinant human serum albumin-interferon-alpha-2a fusion protein (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Hepatitis B | Details | |
| Q101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology) | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Hepatitis B, Chronic | Details | |
| PEGylated interferon alpha-1b (Shanghai Institute of Biological Products) | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Hepatitis B; Neoplasms; Varicella Zoster Virus Infection | Details | |
| SFR-1882 | SFR-1882 | Phase 1 Clinical | Tianjin Sinobiotech Ltd | Anemia; Renal Insufficiency | Details |
| CX-801 | CX-801 | Phase 1 Clinical | Cytomx Therapeutics Inc | Carcinoma, Renal Cell; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| ORB-011 | ORB-011 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| interferon alfa-2b follow-on biologic (Amoytop) | Clinical | Xiamen Amoytop Biotech Co Ltd | Condylomata Acuminata; Hepatitis B; Hepatitis C; Leukemia, Hairy Cell; Lymphoma, Follicular; Melanoma; Sarcoma, Kaposi | Details | |
| interferon-alpha2b (The University Health Network) | Clinical | University Health Network (Uhn) | Coronavirus Disease 2019 (COVID-19) | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | SCH-721015; FE-999326; SCH-209702/SCH-721015; SCH-721015/SCH-209702; TR-002 | Approved | Fkd Therapies, Schering-Plough Labo Nv | Instiladrin, Adstiladrin | United States | Urinary Bladder Neoplasms | Ferring Pharmaceuticals A/S | 2022-12-16 | Adenocarcinoma; Carcinoma, Transitional Cell; Mesothelioma; Pancreatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |